FDA recall record

Nortrel recall — FDA D-0321-2024

Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets.

Class IIIclassification
D-0321-2024official record ID
Feb 21, 2024report date

Recall record at a glance

Official recordD-0321-2024
CategoryDrug Recalls
ClassificationClass III
FDA record statusOngoing
Recalling firmTeva Pharmaceuticals USA, Inc.
Report dateFeb 21, 2024
Recall initiation dateJan 25, 2024
Quantity12,916 cartons
LocationParsippany, NJ, United States

Official product description

Nortrel (norethindrone and ethinyl estradiol tablets USP) 0.5/35, packaged in cartons, each carton contains 3 blister cards, each card contains 28 tablets, Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0555-9008-67

Why the product was recalled

Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets.

Distribution information

nationwide

How to read the classification

FDA Class III generally covers situations in which use of or exposure to the product is not likely to cause adverse health consequences. The classification displayed here is taken from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.

Related recall records

Other records from the same recalling company are shown first when available.

DrugApr 29, 2026

Claravis recall — FDA D-0521-2026

Failed Impurities/Degradation Specifications: Out of specification for specific impurity Tretinoin

Class IIFDA: OngoingTeva Pharmaceuticals USA, Inc